{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:18:58Z","timestamp":1791044338183,"version":"4.1.0"},"reference-count":64,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antivir Chem Chemother"],"published-print":{"date-parts":[[2008,4]]},"abstract":"<jats:p> Among the RNA viruses, other than the retroviruses (that is, HIV), which are dealt with separately in the current FactFile, the most important targets for the development of antiviral agents at the moment are the orthomyxoviruses (that is, influenza), the hepaciviruses (that is, hepatitis C virus [HCV]) and, to a lesser extent, the picornaviruses. Although the uncoating inhibitors amantadine and rimantadine were the first known inhibitors of influenza A, the neuraminidase inhibitors oseltamivir, zanamivir and peramivir have now become the prime antiviral drugs for the treatment of influenza A and B virus infections. For HCV infections, standard treatment consists of the combination of pegylated interferon-\u03b1 with ribavirin, but several other antivirals targeted at specific viral functions such as the HCV protease and\/or polymerase may be expected to soon take an important share of this important market. Still untapped is the potential of a variety of uncoating inhibitors, as well as protease and\/or polymerase inhibitors against the wide spectrum of picornaviruses. While ribavirin has been available for 35 years as a broad-spectrum anti-RNA virus agent, relatively new and unexplored is favipiravir (T-705) accredited with activity against influenza as well as flaviviruses, bunyaviruses and arenaviruses. <\/jats:p>","DOI":"10.1177\/095632020801900204","type":"journal-article","created":{"date-parts":[[2015,3,16]],"date-time":"2015-03-16T17:01:37Z","timestamp":1426525297000},"page":"63-74","source":"Crossref","is-referenced-by-count":8,"title":["<i>Antiviral Chemistry &amp; Chemotherapy<\/i>'s Current Antiviral Agents FactFile 2008 (2nd Edition): RNA Viruses"],"prefix":"10.1177","volume":"19","author":[{"given":"Erik","family":"De Clercq","sequence":"first","affiliation":[{"name":"Rega Institute for Medical Research, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh J","family":"Field","sequence":"additional","affiliation":[{"name":"Department of Veterinary Medicine, University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2008,4,1]]},"reference":[{"key":"bibr1-095632020801900204","doi-asserted-by":"publisher","DOI":"10.2217\/17460913.2.6.583"},{"key":"bibr2-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2007.08.005"},{"key":"bibr3-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1086\/518936"},{"key":"bibr4-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1126\/science.144.3620.862"},{"key":"bibr5-095632020801900204","unstructured":"Hayden FG, Aoki F. Amantadine, Rimantadine, and Related Agents. In Antimicrobial Therapy and Vaccines: Volume II: Antimicrobial Agents, 2nd edn. Edited by Yu VL, Edwards G, McKinnon PS, Peloquin C & Morse GD; pp 705\u2013729."},{"key":"bibr6-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1038\/nature02099"},{"key":"bibr7-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.08.002"},{"key":"bibr8-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20612"},{"key":"bibr9-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1021\/jm0342414"},{"key":"bibr10-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21102"},{"key":"bibr11-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02427-05"},{"key":"bibr12-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.16.9.1345"},{"key":"bibr13-095632020801900204","first-page":"815A","volume":"46","author":"Villano S","year":"2007","journal-title":"Hepatology"},{"key":"bibr14-095632020801900204","first-page":"855A","volume":"46","author":"Rajagopalan PTR","year":"2007","journal-title":"Hepatology"},{"key":"bibr15-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1177\/095632020401500304"},{"key":"bibr16-095632020801900204","first-page":"125","volume":"8","author":"Durantel D","year":"2007","journal-title":"Curr Opin Investig Drugs"},{"key":"bibr17-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1021\/ja963036t"},{"key":"bibr18-095632020801900204","first-page":"175","volume":"4","author":"Hitchcock MJM","year":"1996","journal-title":"International AntiViral News"},{"key":"bibr19-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki018"},{"key":"bibr20-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.11.6.859"},{"key":"bibr21-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2005.10.002"},{"key":"bibr22-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.1.100"},{"key":"bibr23-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.2.290"},{"key":"bibr24-095632020801900204","first-page":"110","volume":"7","author":"Field HJ","year":"1999","journal-title":"International AntiViral News"},{"key":"bibr25-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1021\/jm00008a014"},{"key":"bibr26-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1086\/375069"},{"key":"bibr27-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.11.4492-4499.2005"},{"key":"bibr28-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M510195200"},{"key":"bibr29-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2006.03.045"},{"key":"bibr30-095632020801900204","doi-asserted-by":"crossref","unstructured":"Leveque V, Le Pogam S, Kang H, Antiviral potency of R1479, active compound derived in vivo from prodrug R1626, demonstrated across HCV genotypes 1\u20136 in NS5B recombinant enzymes and HCV replicons. 43rd Annual Meeting of the European Association for the Study of the Liver. 23\u201327 April 2008, Milan, Italy. Abstract 1298.","DOI":"10.1016\/S0168-8278(08)60853-3"},{"key":"bibr31-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn085"},{"key":"bibr32-095632020801900204","doi-asserted-by":"crossref","first-page":"692A","DOI":"10.1002\/hep.21400","volume":"44","author":"Roberts S","year":"2006","journal-title":"Hepatology"},{"key":"bibr33-095632020801900204","doi-asserted-by":"crossref","first-page":"311A","DOI":"10.1002\/hep.21664","volume":"46","author":"Pockros PJ","year":"2007","journal-title":"Hepatology"},{"key":"bibr34-095632020801900204","first-page":"862A","volume":"46","author":"Reddy R","year":"2007","journal-title":"Hepatology"},{"key":"bibr35-095632020801900204","unstructured":"Otto MJ, Robson R, Rodr\u00edguez CA, Pharmacokinetics, Safety, and Tolerability of R7128, a Novel Nucleoside Polymerase Inhibitor for HCV, Following Single Ascending Oral Doses in Healthy Volunteers. 14th International Symposium on Hepatitis C Virus and Related Viruses. 9\u201313 September 2007 Glasgow, Scotland. Abstract 268."},{"key":"bibr36-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1177\/095632020601700203"},{"key":"bibr37-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1126\/science.177.4050.705"},{"key":"bibr38-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.1996.02170340056011"},{"key":"bibr39-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1124\/mol.105.020057"},{"key":"bibr40-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2004.02.009"},{"key":"bibr41-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)80307-6"},{"key":"bibr42-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1177\/106002809502900312"},{"key":"bibr43-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1021\/jm9805384"},{"key":"bibr44-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.10.2444"},{"key":"bibr45-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.12.3907-3916.2003"},{"key":"bibr46-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2424"},{"key":"bibr47-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.4.977-981.2002"},{"key":"bibr48-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.981-986.2005"},{"key":"bibr49-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01051-06"},{"key":"bibr50-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.3.899-909.2006"},{"key":"bibr51-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21774"},{"key":"bibr52-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21781"},{"key":"bibr53-095632020801900204","doi-asserted-by":"crossref","first-page":"823A","DOI":"10.1002\/hep.21752","volume":"46","author":"Verloes R","year":"2007","journal-title":"Hepatology"},{"key":"bibr54-095632020801900204","first-page":"857A","volume":"46","author":"Simmen K","year":"2007","journal-title":"Hepatology"},{"key":"bibr55-095632020801900204","doi-asserted-by":"crossref","first-page":"726A","DOI":"10.1016\/S0168-8278(04)00080-7","volume":"40","author":"Afdhal N","year":"2004","journal-title":"Hepatology"},{"key":"bibr56-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(06)80736-1"},{"key":"bibr57-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00372-06"},{"key":"bibr58-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2005.06.003"},{"key":"bibr59-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(88)90031-9"},{"key":"bibr60-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.10.4006-4008.2004"},{"key":"bibr61-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg405"},{"key":"bibr62-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1038\/363418a0"},{"key":"bibr63-095632020801900204","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709253371302"},{"key":"bibr64-095632020801900204","unstructured":"Hayden FG, Aoki F. Influenza Neraminidase Inhibitors (Oseltamivir and Zanamivr). In Antimicrobial Therapy and Vaccines: Volume II: Antimicrobial Agents, 2nd edn. Edited by Yu VL, Edwards G, McKinnon PS, Peloquin C & Morse GD; pages 773\u2013789."}],"container-title":["Antiviral Chemistry and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/095632020801900204","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/095632020801900204","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T04:38:21Z","timestamp":1725424701000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/095632020801900204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["10.1177\/095632020801900204"],"URL":"https:\/\/doi.org\/10.1177\/095632020801900204","relation":{},"ISSN":["0956-3202","2040-2066"],"issn-type":[{"value":"0956-3202","type":"print"},{"value":"2040-2066","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4]]}}}